{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,13]],"date-time":"2026-10-13T04:21:04Z","timestamp":1791865264641,"version":"4.3.4"},"reference-count":31,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,12,14]],"date-time":"2022-12-14T00:00:00Z","timestamp":1670976000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Health Serv Res"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Huntington\u2019s disease (HD) is a progressive genetic neurodegenerative disease accompanied by mental and neurocognitive disabilities, which requires long-term and comprehensive treatment and care. Information on the health and economic burden of HD is scarce, but essential for conducting health economic analyses, in light of the prospect of new therapies for HD. In this study, we aim to identify values for Health-Related Quality of Life (HRQoL), describe service utilization and costs, and their associations with clinical and socio-demographic variables across all phases of HD.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>A cross-sectional study including 86 patients across all phases of HD. Values of HRQoL were calculated based on EQ-5D-3L index scores. Additionally, health care and societal costs were estimated based on service utilization collected using the Client Service Receipt Inventory (CSRI) and data from the patients\u2019 interviews. Total societal costs included costs of primary and secondary health care services, informal care and productivity loss of the patients. Multiple regression analyses were used to investigate associations between socio-demographic and clinical variables on HRQoL and costs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>HRQoL values declined, while total costs increased across disease severity. Total six-month healthcare costs and total societal costs were \u20ac 18,538 and \u20ac 66,789 respectively. Healthcare and societal costs doubled from early to middle phase, and tripled from middle to advanced disease phase. Main six-month cost components for the three disease phases were informal care costs (\u20ac 30,605) accounting for approximately half the total societal costs, and costs due to production loss (\u20ac 18,907) being slightly higher than the total healthcare costs. Disease severity and gender were found to have the strongest effect on both values of HRQoL and costs.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusions<\/jats:title>\n                <jats:p>Reported values of HRQoL and costs including costs for production loss may be used in modelling the cost-effectiveness of treatment for HD. Our results highlight the crucial role the informal caregivers play in the care provided to HD patients in all disease phases. Future research should focus on the estimation of productivity loss among informal caregivers.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12913-022-08881-8","type":"journal-article","created":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:03:37Z","timestamp":1671062617000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Health related quality of life, service utilization and costs for patients with Huntington\u2019s disease in Norway"],"prefix":"10.1186","volume":"22","author":[{"given":"Marleen R.","family":"van Walsem","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan C.","family":"Frich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"G\u00f3mez Casta\u00f1eda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Emilie Isager","family":"Howe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lasse","family":"Pihlstr\u00f8m","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nada","family":"Andelic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eline","family":"Aas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,12,14]]},"reference":[{"key":"8881_CR1","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1016\/B978-0-12-381328-2.00013-4","volume":"98","author":"MJ Novak","year":"2011","unstructured":"Novak MJ, Tabrizi SJ. Huntington's disease: clinical presentation and treatment. Int Rev Neurobiol. 2011;98:297\u2013323.","journal-title":"Int Rev Neurobiol"},{"key":"8881_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1750-1172-5-40","volume":"5","author":"RA Roos","year":"2010","unstructured":"Roos RA. Huntington's disease: a clinical review. Orphanet J Rare Dis. 2010;5:40.","journal-title":"Orphanet J Rare Dis."},{"key":"8881_CR3","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1002\/mds.25075","volume":"27","author":"T Pringsheim","year":"2012","unstructured":"Pringsheim T, Wiltshire K, Day L, Dykeman J, Steeves T, Jette N. The incidence and prevalence of Huntington's disease: a systematic review and meta-analysis. Mov Disord. 2012;27:1083\u201391.","journal-title":"Mov Disord"},{"key":"8881_CR4","doi-asserted-by":"publisher","first-page":"144","DOI":"10.1159\/000443738","volume":"46","author":"MD Rawlins","year":"2016","unstructured":"Rawlins MD, Wexler NS, Wexler AR, Tabrizi SJ, Douglas I, Evans SJ, et al. The prevalence of Huntington's disease. Neuroepidemiology. 2016;46:144\u201353.","journal-title":"Neuroepidemiology."},{"key":"8881_CR5","volume-title":"Huntingtons disease","author":"G Bates","year":"2014","unstructured":"Bates G, Tabrizi S, Jones L. Huntingtons disease. 4th ed. Oxford: Oxford University Press; 2014.","edition":"4"},{"key":"8881_CR6","doi-asserted-by":"publisher","first-page":"77","DOI":"10.1186\/1750-1172-6-77","volume":"6","author":"RB Veenhuizen","year":"2011","unstructured":"Veenhuizen RB, Kootstra B, Vink W, Posthumus J, van Bekkum P, Zijlstra M, et al. Coordinated multidisciplinary care for ambulatory Huntington's disease patients. Evaluation of 18 months of implementation. Orphanet J Rare Dis. 2011;6:77.","journal-title":"Orphanet J Rare Dis."},{"key":"8881_CR7","doi-asserted-by":"publisher","first-page":"192","DOI":"10.1016\/j.brainresbull.2009.06.017","volume":"80","author":"RB Veenhuizen","year":"2009","unstructured":"Veenhuizen RB, Tibben A. Coordinated multidisciplinary care for Huntington's disease. An outpatient department Brain Res Bull. 2009;80:192\u20135.","journal-title":"An outpatient department Brain Res Bull"},{"issue":"2\u20133","key":"8881_CR8","doi-asserted-by":"publisher","first-page":"175","DOI":"10.1016\/j.brainresbull.2006.10.027","volume":"72","author":"MA Nance","year":"2007","unstructured":"Nance MA. Comprehensive care in Huntington's disease: a physician's perspective. Brain Res Bull. 2007;72(2\u20133):175\u20138.","journal-title":"Brain Res Bull"},{"key":"8881_CR9","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1111\/j.1365-2648.2011.05727.x","volume":"68","author":"JK Williams","year":"2012","unstructured":"Williams JK, Skirton H, Barnette JJ, Paulsen JS. Family carer personal concerns in Huntington disease. J Adv Nurs. 2012;68:137\u201346.","journal-title":"J Adv Nurs"},{"key":"8881_CR10","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1111\/j.1365-2648.2008.04946.x","volume":"65","author":"JK Williams","year":"2009","unstructured":"Williams JK, Skirton H, Paulsen JS, Tripp-Reimer T, Jarmon L, McGonigal Kenney M, et al. The emotional experiences of family carers in Huntington disease. J Adv Nurs. 2009;65:789\u201398.","journal-title":"J Adv Nurs"},{"key":"8881_CR11","doi-asserted-by":"publisher","first-page":"RRN1206","DOI":"10.1371\/currents.RRN1206","volume":"3","author":"M Busse","year":"2011","unstructured":"Busse M, Al-Madfai DH, Kenkre J, Landwehrmeyer GB, Bentivoglio A, Rosser A, et al. Utilisation of healthcare and associated Services in Huntington's disease: a data mining study. PLoS currents. 2011;3:RRN1206.","journal-title":"PLoS currents"},{"key":"8881_CR12","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1111\/hsc.12174","volume":"23","author":"M Rothing","year":"2015","unstructured":"Rothing M, Malterud K, Frich JC. Balancing needs as a family caregiver in Huntington's disease: a qualitative interview study. Health & social care in the community. 2015;23:569\u201376.","journal-title":"Health & social care in the community"},{"key":"8881_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1016\/0168-8510(90)90421-9","volume":"16","author":"TEQ Group","year":"1990","unstructured":"TEQ Group. EuroQol--a new facility for the measurement of health-related quality of life. Health Policy. 1990;16:199\u2013208.","journal-title":"Health Policy"},{"key":"8881_CR14","doi-asserted-by":"publisher","first-page":"247","DOI":"10.1097\/00005650-199303000-00006","volume":"31","author":"CA McHorney","year":"1993","unstructured":"McHorney CA, Johne W, Anastasiae R. The MOS 36-item short-form health survey (SF-36): II. Psychometric and clinical tests of validity in measuring physical and mental health constructs. Med Care. 1993;31:247\u201363.","journal-title":"Med Care"},{"key":"8881_CR15","doi-asserted-by":"publisher","first-page":"117","DOI":"10.1111\/j.1399-0004.2011.01823.x","volume":"81","author":"MB Hocaoglu","year":"2012","unstructured":"Hocaoglu MB, Gaffan EA, Ho AK. The Huntington's disease health-related quality of life questionnaire (HDQoL): a disease-specific measure of health-related quality of life. Clin Genet. 2012;81:117\u201322.","journal-title":"Clin Genet"},{"key":"8881_CR16","doi-asserted-by":"publisher","first-page":"1793","DOI":"10.1007\/s00415-011-6405-2","volume":"259","author":"MB Hocaoglu","year":"2012","unstructured":"Hocaoglu MB, Gaffan EA, Ho AK. Health-related quality of life in Huntington's disease patients: a comparison of proxy assessment and patient self-rating using the disease-specific Huntington's disease health-related quality of life questionnaire (HDQoL). J Neurol. 2012;259:1793\u2013800.","journal-title":"J Neurol"},{"key":"8881_CR17","doi-asserted-by":"publisher","first-page":"159","DOI":"10.3233\/JHD-130051","volume":"2","author":"J Read","year":"2013","unstructured":"Read J, Jones R, Owen G, Leavitt BR, Coleman A, Roos RA, et al. Quality of life in Huntington's disease: a comparative study investigating the impact for those with pre-manifest and early manifest disease, and their partners. Journal of Huntington's disease. 2013;2:159\u201375.","journal-title":"Journal of Huntington's disease"},{"key":"8881_CR18","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1002\/mds.22412","volume":"24","author":"AK Ho","year":"2009","unstructured":"Ho AK, Gilbert AS, Mason SL, Goodman AO, Barker RA. Health-related quality of life in Huntington's disease: which factors matter most? Mov Disord. 2009;24:574\u20138.","journal-title":"Mov Disord"},{"key":"8881_CR19","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1007\/s10198-019-01092-9","volume":"20","author":"A Hawton","year":"2019","unstructured":"Hawton A, Green C, Goodwin E, Harrower T. Health state utility values (QALY weights) for Huntington\u2019s disease: an analysis of data from the European Huntington\u2019s disease network (EHDN). Eur J Health Econ. 2019;20:1335\u201347.","journal-title":"Eur J Health Econ"},{"key":"8881_CR20","doi-asserted-by":"publisher","first-page":"1588","DOI":"10.1111\/ene.13107","volume":"23","author":"C Jones","year":"2016","unstructured":"Jones C, Busse M, Quinn L, Dawes H, Drew C, Kelson M, et al. The societal cost of Huntington's disease: are we underestimating the burden? Eur J Neurol. 2016;23:1588\u201390.","journal-title":"Eur J Neurol"},{"key":"8881_CR21","doi-asserted-by":"publisher","first-page":"1043","DOI":"10.3111\/13696998.2013.818545","volume":"16","author":"V Divino","year":"2013","unstructured":"Divino V, Dekoven M, Warner JH, Giuliano J, Anderson KE, Langbehn D, et al. The direct medical costs of Huntington's disease by stage. A retrospective commercial and Medicaid claims data analysis. J Med Econ. 2013;16:1043\u201350.","journal-title":"J Med Econ"},{"key":"8881_CR22","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1186\/s12913-019-4806-6","volume":"19","author":"G Silva-Paredes","year":"2019","unstructured":"Silva-Paredes G, Urbanos-Garrido RM, Inca-Martinez M, Rabinowitz D, Cornejo-Olivas MR. Economic burden of Huntington's disease in Peru. BMC Health Serv Res. 2019;19:1017.","journal-title":"BMC Health Serv Res"},{"key":"8881_CR23","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1186\/s12883-019-1556-3","volume":"19","author":"C Ohlmeier","year":"2019","unstructured":"Ohlmeier C, Saum KU, Galetzka W, Beier D, Gothe H. Epidemiology and health care utilization of patients suffering from Huntington's disease in Germany: real world evidence based on German claims data. BMC Neurol. 2019;19:318.","journal-title":"BMC Neurol"},{"key":"8881_CR24","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1212\/WNL.29.1.1","volume":"29","author":"I Shoulson","year":"1979","unstructured":"Shoulson I, Fahn S. Huntington disease: clinical care and evaluation. Neurology. 1979;29:1\u20133.","journal-title":"Neurology."},{"key":"8881_CR25","first-page":"271","volume-title":"Assessment of functional capacity in neurodegenerative movement disorders: Huntington\u2019s disease as a prototype","author":"I Shoulson","year":"1989","unstructured":"Shoulson I, Kurlan R, Rubin AJ, Goldblatt D, Behr J, Miller C, et al. Assessment of functional capacity in neurodegenerative movement disorders: Huntington\u2019s disease as a prototype. Quantification of neurologic deficit Boston, MA: Butterworths; 1989. p. 271\u201383."},{"key":"8881_CR26","volume-title":"Measuring mental health needs","author":"J Beeacham","year":"2001","unstructured":"Beeacham J, Knapp MR. Costing psychiatric interventions. In: Thornocroft GBC, Wing JK, editors. Measuring mental health needs. London: Gaskell; 2001."},{"key":"8881_CR27","first-page":"115","volume":"42","author":"OJ Handley","year":"2011","unstructured":"Handley OJ, van Walsem M, Juni P, Bachoud-Levi A-C, Bentivoglio AR, Bonelli RM, et al. Study protocol of Registry - version - 2.0 - European Huntington's disease network (EHDN). Hygeia. Public Health. 2011;42:115\u201382.","journal-title":"Public Health"},{"key":"8881_CR28","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1186\/s12955-018-1029-1","volume":"16","author":"K Stavem","year":"2018","unstructured":"Stavem K, Augestad LA, Kristiansen IS, Rand K. General population norms for the EQ-5D-3 L in Norway: comparison of postal and web surveys. Health Qual Life Outcomes. 2018;16:204.","journal-title":"Health Qual Life Outcomes"},{"key":"8881_CR29","doi-asserted-by":"publisher","first-page":"700","DOI":"10.1111\/scs.12098","volume":"28","author":"M Rothing","year":"2014","unstructured":"Rothing M, Malterud K, Frich JC. Caregiver roles in families affected by Huntington's disease: a qualitative interview study. Scand J Caring Sci. 2014;28:700\u20135.","journal-title":"Scand J Caring Sci"},{"key":"8881_CR30","doi-asserted-by":"publisher","first-page":"931","DOI":"10.12740\/PP\/34496","volume":"49","author":"J Domaradzki","year":"2015","unstructured":"Domaradzki J. The impact of Huntington disease on family Carers: a literature overview. Psychiatr Pol. 2015;49:931\u201344.","journal-title":"Psychiatr Pol"},{"key":"8881_CR31","doi-asserted-by":"publisher","first-page":"124","DOI":"10.1186\/s13023-015-0324-8","volume":"10","author":"MR van Walsem","year":"2015","unstructured":"van Walsem MR, Howe EI, Iversen K, Frich JC, Andelic N. Unmet needs for healthcare and social support services in patients with Huntington's disease: a cross-sectional population-based study. Orphanet J Rare Dis. 2015;10:124.","journal-title":"Orphanet J Rare Dis"}],"container-title":["BMC Health Services Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-08881-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12913-022-08881-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12913-022-08881-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,15]],"date-time":"2022-12-15T00:04:09Z","timestamp":1671062649000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmchealthservres.biomedcentral.com\/articles\/10.1186\/s12913-022-08881-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12,14]]},"references-count":31,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2022,12]]}},"alternative-id":["8881"],"URL":"https:\/\/doi.org\/10.1186\/s12913-022-08881-8","relation":{},"ISSN":["1472-6963"],"issn-type":[{"value":"1472-6963","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,12,14]]},"assertion":[{"value":"27 December 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 November 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 December 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Regional Committees for Medical and Health Research Ethics South Eastern Norway (ref. 2013\/2089) and performed in accordance with the Declaration of Helsinki. Informed consent to participate in the study was obtained for all participants.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests. Oslo University Hospital has received a fee from Roche for consulting performed by L.P., unrelated to the present work.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1527"}}